| scholarly article | Q13442814 |
| P50 | author | Ingrid E Lundberg | Q38324999 |
| P2093 | author name string | Lindblad S | |
| Pettersson E | |||
| Gunnarsson I | |||
| Ringertz B | |||
| Kanerud L | |||
| P433 | issue | 10 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 1089-1094 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | British Journal of Rheumatology | Q27709787 |
| P1476 | title | Predisposing factors in sulphasalazine-induced systemic lupus erythematosus | |
| P478 | volume | 36 |
| Q33759553 | A review of gastrointestinal manifestations of systemic lupus erythematosus. |
| Q34587103 | Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine |
| Q34673370 | Arylamine N-acetyltransferases and drug response |
| Q46812622 | Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis? |
| Q57350977 | Development of lupus‐related side‐effects in patients with early RA during sulphasalazine treatment—the role of IL‐10 and HLA |
| Q35816996 | Drug-induced glomerular disease: immune-mediated injury |
| Q38002687 | Inflammatory bowel disease and lupus: a systematic review of the literature |
| Q34339975 | Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group |
| Q34999557 | Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications |
| Q37133431 | N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease |
| Q37710516 | Pharmacogenomics in the treatment of inflammatory bowel disease |
| Q46496343 | Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers |
| Q34031291 | Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. |
| Q33436278 | Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis |
| Q40099981 | Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus |
| Q24647121 | Sulfasalazine-induced immune thrombocytopenia |
| Q89926938 | The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q37124665 | Toxic Epidermal Necrolysis-Like Lesions and Systemic Lupus Erythematosus Possibly Triggered by Sulfasalazine. |
| Q79904778 | [Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal] |
Search more.